Look back at pharma news in week to September 21

By Barbara Obstoj-Cardwell. Editor

Among last week’s regulatory events, new of US Food and Drug Administration approval of Teva Pharmaceutical Industries’ migraine prophylaxis drug Ajovy (fremanezumab) is seen as a turning point for the Israeli company. There was also FDA approval for AstraZeneca’s leukemia drug Lumoxiti, and the agency lifted the partial clinical hold on Mersana’s XMT-1522 cancer drug, but the company’s shares fell. Allergan’s acquisition of medical aesthetics firm Bonti is seen as good news for the firm. On the research front, Viking Therapeutics soared on strong clinical data for its liver disease drug VK2809, but it may not be the first to come to the market.

Teva’s migraine approval confirmed, limited impact on Aimovig outlook